The Future is Now for Biomedical Research in Canada
By Dr David B. Shindler, CEO, Milestone Medica Corporation
Nearly 20 years ago, the National Biotechnology Advisory Committee (NBAC) reported to the federal government that Canada had serious limitations in its capability to commercialize biotechnology inventions.
Other stories mentioning these organizations, people and topics
| People: | Dr David B. Shindler, CEO, Milestone Medica Corporation |
Other News
Events For Leaders in
Science, Tech, Innovation, and Policy
Discuss and learn from those in the know at our virtual and in-person events.
See Upcoming Events
You have 0 free articles remaining.
Don't miss out - start your free trial today.
Start your FREE trial Already a member? Log in
By using this website, you agree to our use of cookies. We use cookies to provide you with a great experience and to help our website run effectively in accordance with our Privacy Policy and Terms of Service.